川芎嗪联合贝纳普利防治GK大鼠并发肾病的实验研究及机理探讨
|
摘要
目的:初步观察川芎嗪联合贝那普利对GK大鼠并发肾病的大鼠肾组织TNF-α、ICAM-1、OPN等表达水平的防治作用并探讨其调控作用的可能机制;探讨DN病变程度与炎症表达的关系,并进一步探讨糖尿病肾病的发病机制,寻找早期诊断及评价DN病变的新指标。
方法:将40只雄性GK大鼠随机分为模型组、贝那普利组、川芎嗪组、川芎嗪+贝那普利组;每组10只。模型组,按5ml·kg~(-1)·d~(-1)灌服生理盐水;贝那普利组,按1.6mg·kg~(-1)·d~(-1)灌服贝那普利悬液;川芎嗪组,按150mg·kg~(-1)·d~(-1)灌胃(其浓度为20mg/ml);川芎嗪+贝那普利组,川芎嗪按150mg·kg~(-1)·d~(-1)灌服,加灌贝那普利悬液(按1.6mg·kg~(-1)·d~(-1));共16周。实验第8周、第12周和第16周将大鼠放入代谢笼中,收集24h尿液,测定24h尿蛋白定量;治疗16周后,将大鼠用3%戊巴比妥钠腹腔麻醉后剖腹,摘取肾脏。反转录聚合酶链反应法(RT-PCR)测肾组织TNF-α、OPN含量,免疫组化检测肾脏ICAM-1的表达,并测定各组大鼠血IL-6和尿RBP水平。
结果:与其它组比较,模型组大鼠血糖明显增高(P＜0.05),24h尿蛋白定量明显升高(P＜0.05),肾组织TNF-α、ICAM-1、OPN表达明显增加(P＜0.05,或p＜0.01);血IL-6和尿RBP、24h尿蛋白等指标增加(P＜0.05,或p＜0.01)。川芎嗪联合贝那普利能降低血糖、TG和TC;下调肾组织TNF-α、ICAM-1、OPN表达水平,降低血清肌酐、尿素氮水平,提高内生肌酐清除率,减少尿白蛋白的排泄,降低IL-6水平;从而改善DN大鼠的肾功能。
结论:川芎嗪联合贝那普利能降低糖尿病肾病大鼠血糖水平,改善DN大鼠肾功能,改善肾组织炎症病变和抗凝作用。下调肾组织TNF-α、ICAM-1、OPN表达和降低IL-6水平可能为其作用机制之一。
Objective:To observe ligustrazine combined with benazepil tablets prevention and cure in expression level of intercellular adhesion molecule-1(ICAM-1)、tumour necrosis factor-α(TNF-α) and osteopontin (OPN) in GK rats nephridial tissue tentatively and evalute the possible mechanisms of effects on diabetic neuropathy(DN) on earlier period. To probe into the connection between diabetic neuropathy and inflammatory to open out the possible mechanisms of DN for appraising and diagnosing new quideline on diabetic neuropathy on earlier period.
Methods:Forty GK male rats were randomly divided into four groups: 10 every groups,respectively for model group,ligustrazine group, benazepil group and ligustrazine combined with benazepil group.Drench with NS 5ml·kg~(-1)·d~(-1)、benazepill.6mg·kg~(-1)·d~(-1)、ligustrazine 150mg·kg~(-1)·d~(-1)、ligustrazine combined with benazepil(150mg·kg~(-1)·d~(-1)+1.6mg·kg~(-1)·d~(-1)) to rats respectively,according to the group in 16 weeks.Puting big mouses into metabolism cages in the 8th week,the 12th week and the16th week,collecting urine to determine quantitation of Urine protein in 24 hours.Treat for 16 weeks,anaesthetize the big mouse by 3% pentobarbital,then cut open the belly of rats and pick its kidney, examine TNF-αand OPN content in renal organize by means of RT-PCR and ICAM-1 content by means of immunohistochemistry,and determine IL-6 level in blood serum and RBP level in emiction of every group.
Result:Compared with other group,the blood glucose of model group rats increase obviously(P＜0.05),quantitation of 24h Urine protein rise obviously(P＜0.05),degrade the express level of TNF-α、ICAM-1 and OPN in renal organizes increase obviously(P＜0.05,或p＜0.01);blood Indexes such as IL-6 and RBP level in emiction are improved(P＜0.05,或p＜0.01). ligustrazine combined with benazepil tablets can protect the kidney for lowerring blood glucose、TG and TC、degrading TNF-α、ICAM-1 and OPN express level in renal organize,decreasing serum albumin、blaood urea mitrogen and increasing creatinine clearance,at the same time,reducing Urine protein and IL-6 level
Conclusion:ligustrazine combined with benazepil can reduce great mouse blood glucose level of diabetic rats and improve nephric tubule pathological change,moreover;it can play its roles depend on resisting inflammation and anticoagulatory function.One of the possible mechanisms of DN is to degrade TNF-α、ICAM-1 and OPN express level in renal organize and reduce IL-6 level in blood serum.
方法:将40只雄性GK大鼠随机分为模型组、贝那普利组、川芎嗪组、川芎嗪+贝那普利组;每组10只。模型组,按5ml·kg~(-1)·d~(-1)灌服生理盐水;贝那普利组,按1.6mg·kg~(-1)·d~(-1)灌服贝那普利悬液;川芎嗪组,按150mg·kg~(-1)·d~(-1)灌胃(其浓度为20mg/ml);川芎嗪+贝那普利组,川芎嗪按150mg·kg~(-1)·d~(-1)灌服,加灌贝那普利悬液(按1.6mg·kg~(-1)·d~(-1));共16周。实验第8周、第12周和第16周将大鼠放入代谢笼中,收集24h尿液,测定24h尿蛋白定量;治疗16周后,将大鼠用3%戊巴比妥钠腹腔麻醉后剖腹,摘取肾脏。反转录聚合酶链反应法(RT-PCR)测肾组织TNF-α、OPN含量,免疫组化检测肾脏ICAM-1的表达,并测定各组大鼠血IL-6和尿RBP水平。
结果:与其它组比较,模型组大鼠血糖明显增高(P＜0.05),24h尿蛋白定量明显升高(P＜0.05),肾组织TNF-α、ICAM-1、OPN表达明显增加(P＜0.05,或p＜0.01);血IL-6和尿RBP、24h尿蛋白等指标增加(P＜0.05,或p＜0.01)。川芎嗪联合贝那普利能降低血糖、TG和TC;下调肾组织TNF-α、ICAM-1、OPN表达水平,降低血清肌酐、尿素氮水平,提高内生肌酐清除率,减少尿白蛋白的排泄,降低IL-6水平;从而改善DN大鼠的肾功能。
结论:川芎嗪联合贝那普利能降低糖尿病肾病大鼠血糖水平,改善DN大鼠肾功能,改善肾组织炎症病变和抗凝作用。下调肾组织TNF-α、ICAM-1、OPN表达和降低IL-6水平可能为其作用机制之一。
Objective:To observe ligustrazine combined with benazepil tablets prevention and cure in expression level of intercellular adhesion molecule-1(ICAM-1)、tumour necrosis factor-α(TNF-α) and osteopontin (OPN) in GK rats nephridial tissue tentatively and evalute the possible mechanisms of effects on diabetic neuropathy(DN) on earlier period. To probe into the connection between diabetic neuropathy and inflammatory to open out the possible mechanisms of DN for appraising and diagnosing new quideline on diabetic neuropathy on earlier period.
Methods:Forty GK male rats were randomly divided into four groups: 10 every groups,respectively for model group,ligustrazine group, benazepil group and ligustrazine combined with benazepil group.Drench with NS 5ml·kg~(-1)·d~(-1)、benazepill.6mg·kg~(-1)·d~(-1)、ligustrazine 150mg·kg~(-1)·d~(-1)、ligustrazine combined with benazepil(150mg·kg~(-1)·d~(-1)+1.6mg·kg~(-1)·d~(-1)) to rats respectively,according to the group in 16 weeks.Puting big mouses into metabolism cages in the 8th week,the 12th week and the16th week,collecting urine to determine quantitation of Urine protein in 24 hours.Treat for 16 weeks,anaesthetize the big mouse by 3% pentobarbital,then cut open the belly of rats and pick its kidney, examine TNF-αand OPN content in renal organize by means of RT-PCR and ICAM-1 content by means of immunohistochemistry,and determine IL-6 level in blood serum and RBP level in emiction of every group.
Result:Compared with other group,the blood glucose of model group rats increase obviously(P＜0.05),quantitation of 24h Urine protein rise obviously(P＜0.05),degrade the express level of TNF-α、ICAM-1 and OPN in renal organizes increase obviously(P＜0.05,或p＜0.01);blood Indexes such as IL-6 and RBP level in emiction are improved(P＜0.05,或p＜0.01). ligustrazine combined with benazepil tablets can protect the kidney for lowerring blood glucose、TG and TC、degrading TNF-α、ICAM-1 and OPN express level in renal organize,decreasing serum albumin、blaood urea mitrogen and increasing creatinine clearance,at the same time,reducing Urine protein and IL-6 level
Conclusion:ligustrazine combined with benazepil can reduce great mouse blood glucose level of diabetic rats and improve nephric tubule pathological change,moreover;it can play its roles depend on resisting inflammation and anticoagulatory function.One of the possible mechanisms of DN is to degrade TNF-α、ICAM-1 and OPN express level in renal organize and reduce IL-6 level in blood serum.
引文
[1]Phillips AO,Steadman R.Diabetic nephropathy:the central role of renal proximal tubular cells in tubulointerstitial injury.Histol Histop -athol 2002,17(1):247-52.
[2]Tsilibary EC.Microvascular basement membranes in diabetes mellitus.J Pathol,2003,200(4):537-46.
[3]邝安.糖尿病在中国.长沙:湖南科技出版社,1989,277-278
[4]Li Ls.End-stage renal disease in China[J].Kidney Int,1996,49:287.
[5]Raij L.Recommendation for the management of special populations:renal disease in diabetes.Am J Hypertens,2003,16(11Pt2):46-49
[6]佟之复,李宁华,苗俊梅等.2型糖尿病肾病流行病学研究进展[J].中国老年学杂志,2001,21(3):241-243.
[7]王竹兰,冯根宝,王燕燕,等.642例糖尿病患者肾脏病变的调查及临床分析[J].中国糖尿病杂志,1995,3(3):7.
[8]Anderson AR,et al.Diabetic nephropathy in type 1(insulin-dependent) diabetes:An epidemiological study.Diabetologia,1983,23 B496
[9]钟学礼.临床糖尿病学.上海:上海科技出版社.1987,271-273
[10]张永钢,韩梅,温进坤.骨桥蛋白的病理功能冲国老年学杂志,2005;25:230-231
[11]Bemard Am,Vyskail AA,Mahieu PX,et al.Assessment of urinary retindbinding protein as an index of proximal tubular injury.Cli Chem,1987,33:775
[12]Wolf G,Ziyadeh FN,Stahl RA.Angiotensin Ⅱ stimulates expression of transforming growth factor beta receptor type Ⅱ in cultured mouse proximal tubular cells[J].JMohned,1999,77(5):556-564
[13]苏小惠.中西医结合治疗糖尿病肾病40例临床观察.辽宁中医杂志.2006,33(1):92-93
[14]林楠,宋王宣,薛丽.通心络胶囊治疗糖尿病肾病疗效观察.中国误诊学杂志.2005,5(9):1663-1664
[15]谢席胜,黄宗文.中西医结合治疗糖尿病的优势评价.中国临床康复,2006,10(35):151-154
[16]吕仁和.糖尿病及其并发症中西医诊治学[M].北京:人民卫生出版社,2001,328
[17]倪青.糖尿病。肾病的中医药研究思路与方法[J].中国医药学报,1998,13(4):60-62
[18]倪青.活血化瘀法治疗糖尿病肾病42例.南京中医药大学学报,2003,19(6):380
[19]魏连波.糖尿病肾病病因病机的探讨.福建中医药,2003,34(2:46-47
[20]曲晓璐,陈大舜,姚欣艳,等.1718例2型糖尿病患者糖尿病肾病发病率及其中医证型分布特点.中国中西医结合肾病杂志,2003,4(12):713
[21]成玉斌,罗仁,胡志飞,等.糖尿病肾病中医辨证分型荟萃分析.中国中医基础医学杂志,2000,6(5):49
[22]杨霓芝,王立新,廖平平.248例糖尿病肾病患者分期辨证分析.广州中医药大学学报,1998,15(4):260
[23]杨霓芝,李芳,徐大基,等.糖尿病肾病分期辨证治疗的探讨.辽宁中医杂志,1999,26(1):16
[24]陈辉,汤水福,赵萍.活血化瘀法治疗早期糖尿病肾病及其对肾血流参数的影响[J].中国中西医结合肾病杂志.2005,6(1):31
[25]郭赛珊.治疗糖尿病肾病的经验体会.中国中西医结合杂志,1996,16(1):3
[26]吕仁和,时振声.糖尿病肾病的中医诊治[J].北京中医,1989,8(2):8-10.
[27]林兰.中西医结合糖尿病学.北京:中国医药科技出版社,1999:394
[28]熊曼琪,苗理平.加味桃核承气汤对糖尿病鼠肾超微结构的影响[J].中国医药学报,1990,5(5):25-27.
[29]张泽生,袁遵守,杨新军,等.益肾扶脾化瘀降浊法治疗糖尿病肾病64例临床观察.新中医,2001,33(11):36
[30]林兰.糖尿病中西医结合论治[M].北京:北京科学技术出版社1992,229.
[31]高彦彬,易京红.糖肾宁治疗糖尿病肾病的临床研究.中医杂志,1991,32(7):31
[32]李毅.祝堪予老中医活血化瘀法治疗糖尿病经验[J].山东中医学院报.1986,9(5):27
[33]高彦彬,易京红.中医药辩治糖尿病肾病100例临床分析[J].中医杂志,1991,32(7):31-32
[34]邓权.益肾活血法治疗糖尿病肾病62例[J].浙江中医杂志,1996,31(7):317-318
[35]耿嘉,栗德林.糖尿病肾病病因病机的辩证.首都医药,2005,3:(12):112
[36]吉勤,王清,李桢,等.活血化瘀法改善糖尿病肾病水肿的疗效观察[J].中国中西 医结合肾病杂志,2006,7(2):109
[37]孙树良,郑杨.活血化瘀法治疗糖尿病肾病临床观察[J].辽宁中医学院学报,2006,8(2):84-85
[38]睦书魁,李细贵.从瘀论治糖尿病57例临床观察[J].中国中西医结合杂志,1992,12(1):43.11
[39]耿嘉,栗德林.糖尿病肾病病因病机的辩证.首都医药,2005,3:(12):112
[40]张宗铭.糖尿病瘀血产生的机理、辨证与治疗(J)安徽中医学院学报,1989,(2):53-56
[41]翁维良.糖尿病人”瘀血”的研究(J)中医杂志,1982,1(1):46-48
[42]吴春林.试析糖尿病从瘀论治的理论基础(J).长春中医学院学报,1997,13(4):3
[43]刘冰冰.糖尿病神经病变患者血液流变性与微循环指标分析.中国血液流变学杂志.2000,10(1):47-49
[44]石志芸,等.血栓相关分子标志物在糖尿病血瘀证中的临床意义(J)中医杂志,1999,40(9):554-555
[45]曾庆祥.糖尿病肾病从瘀论治[J].吉林中医药,2001,21(3):14
[46]林兰,倪青,董彦敏.糖尿病肾病中西医结合治疗热点问题述评[J].中西医结合,2000,7:50.
[47]刘新明,刘晓城.糖尿病肾病的发病机制与治疗现状.中国中西医结合肾病杂,2004,5(9):553-554
[48]施赛珠,王倩,董彩云.Ⅱ型糖尿病中瘀血证和益气活血药预防其血管病变的疗效观察.中医杂志,1989,30(6):341
[49]方立成.化瘀养阴汤治疗Ⅱ型糖尿病56例临床观察.湖南中医学院学报,1994,14(2):20
[50]赵淑华,严庆良.糖尿病患者平均血小板体积和高脂变化的研究.中华内分泌代谢杂志,1998,14(1):42
[51]梁晓春,王秀定,张孟仁.糖尿病患者血浆TXB2.6-K-PGFla水平、全血粘度与血瘀证的微血管病的关系.中国中西医结合杂志,1992,12(5):29
[52]Navarro JF,Mora C,MacaM,et al.Inflammationtory parameters are independently associated with urinary albumin in type 2 diabetes mellitus.Am J Kidney Dis,2003,42:53-61.
[53]Anders H J,Vielhauer V,Schlondorff D.Chemokines and chemokine receptors are involved in the resolution or progression of renal disease.Kidney Int,2003,63:401-415.
[54]Mensah-Brown EPK,Obineche EN,Galadad S,et al.Streptozotocin-induced diabetic nephropathy in rats:The role of inflammatory cytokines.CYTOKI NE,2005,31(3):180-190.
[55]Lee SH,Lee TW,Ihrn CG;et al.Genetics of diabetic nephropathy in type 2 DM:candidate gene analysis for the pathogenic role ofinflammation.Nephrology,2005,10:S32-S36.
[56]Navarro JF,Mora C.Role of inflammation in diabetic complications.Nephrology dialysis transplantation,2005,20(12):2601-2604.
[57]Sfakianaki M,Xydakis D,Papadogiannakia A,et al.1 Low-grade inflammation is correlated to diabetic nephropathy in type 2 diabetes mellitus.Diabetologia,2005,48:A375-A376.
[58]李静,李荣山.巨噬细胞在大鼠糖尿病肾病发病机制中的作用.中国中西医结合肾病杂志,2005,6:79-82.
[59]Chow F,Ozols E,Nikolic Paterson DJ,et al.Macrophages in mouse type 2diabetic nephropathy correlation with diabetic state and progression renal injury.Kidney Int,2004,65:116-128.
[60]Sassy-Prigent C,Heudes D,Mandet C,et al.Early glomerular macrophage recruitment in streptozotocin- induced diabetic rats.Diabetes,2000,49:466-475.
[61]Sheu JR,Kan YC,Hunn WC,el al.Mechanisms involved in the anliplalelel aclivilv of T M P in humanplalelels.Thrornh-Res,1997,88(3):259-270
[62]王海松,谢春光.益肾糖泰颗粒对糖尿病大鼠肾脏病变的影响[N].成都中医药大学学报,2000,23(1):49-57
[63]李建生,郑士荣.中药糖肾安队实验性糖尿病大鼠肾脏病变的作用[J]河南中医1995,15(5):282-284
[64]武慧,杜宏武,谢道俊,等.益气养阴活血化淤法为主治疗老年早期糖尿病肾病31例[N].安徽中医学院学报,2001,20(1):16-18
[65]姜春华.活血化瘀研究[M].上海:上海科技出版社,1981,1:341.
[66]Abdel-Wahab N,Weston BS,et al.Connective tissue growth factor and regulation of the mesangial cell cycle:role in cellular hypertrophy[J].J Am Soc Nephrol,2002,13(10):2437.
[67]Okada S,Shikata K,et al.Intercellular adhesion molecule-1-deficient mice are resistant against renal injury after induction of diabetes[J].Diabetes,2003 Oct,52(10):2586.
[68]Forbes JM,Cooper ME,et al.Role of advanced glycation end products in diabetic nephropathy[J].J Am Soc Nephrol,2003,14(8 Supp 13):S254.
[69]Rosenherv M,Correct ROTTar R.PaLhohenesis and risk factor for diahelic Nephropalhv.In Jacohson HR,Striker GE,KlahrS.The principles and practice of Nephroloay.SL Lowis Mos-hv.1995,330
[70]Jones,and Alebowain Phillips.Regulation of renal proximal tubular epithelial cell hyaluronan generation:Implication for diabetic nephropathy.Kidney Int,2000,59(1):1739-1749
[71]Li JM,Shah AM.ROS generation by nonphagocytic NADPH oxidase:potential relevance in diabetic nephropathy[J].J Am Soc Nephrol,2003 Aug,14(8 Suppl 3):S221
[72]Doric A.Warram JH,Krolewski AS Geneticsusceptihilitv Lonephropathv in insulin dependent diabetes:from epidemioloay Lomolecular nenetics.Diabetes/Metabolism Review,1995,11:287
[73]Hotta N.Risk factors for diabetic complications:Abnormality of polyol metabolism[J].Nippon Rinsho,2002,60(Suppl 10):60-66
[74]Yang Q,Kaji R,Takagi T,et al.Abnormal axonal inward rectifier in s treptozocin induced experimental diabetic neuropathy.Brain.2001 Jun,124(Pt6):1149-55
[75]Raj Ds,Choudhury D,Welboume TC,et al.Advanced glycation end products:a Nephrologist's perspective[J].Am J Kidney Dis.2000,35(3):365-380
[76]Boyd-White J,Williams JC.Effect of cross-linking on matrix perm- eability.A model for AGE-modified basement membranes[J].Diabetes.1996,45(3):348-353
[77]Balkan J,Kanbagli O,Mehmetcik G,et al.Increased lipid peroxidation in serum and low-density Lipoproteins associated with aging in humans[J].Int J Vitam Nutr Res.2002,72(5):315-320
[78]Zhou G,Li C,Cai L.Advanced glycation end-products induceconnec tive tissue growth factor-mediated renal fibrosis predomi nantly through transforming growth factor betaindependent path way[J].Am J Pathol,2004,165:2033-2043.
[79]Wolf G,Ziyadeh FN,Stahl RA.Angiotensin Ⅱ stimulates expression of transforming growth factor beta receptor type Ⅱ in cultured mouse proximal tubular cells[J].JMohned,1999,77(5):556-564
[80]Hodgkinson AD,Millward BA,Demaine AG.Polymorphism of the glucose transporter(GLUT1) gene are associated with diabetic nephropathy[J].Kiney Int,2001,59(3),985.
[81]谭燕,杨永年.AEGs在糖尿病慢性并发症中的作用.中国糖尿病杂志,1990,7:292
[82]秦洁,张志利.糖尿病肾病发病机制的研究进展.山西医科大学学报,2002,33(6):576-577
[83]胡伟新,刘志红,黎磊石,等.IgA肾病患者尿自介素6检测的意义.中华肾脏病杂志,1994,10(4):203
[84]Rosenberg M,Correa-Rottar R.Pathogenesis and risk factors for diabetic nephropathy.In:Jacobson HR,Striker GE,Klahr S.The principle and practice of nephrology.Stlowis Mosby,1995:330
[85]Osende JI,Badimon JJ,Fuster V,et al.Blood thrombogenicity in type2diabetes mellitus patients is associated with glycemiccontrol[J].J AM Coll Cardiol,2001,38(5):1307-1312.
[86]Abbou HE.Growth factors and diabetic nephrology:an overview[J].Kidney Int Suppl,1997,60:S3-6
[87]Napolic C,Triaaiani M,Palumbo G,et al.Glvcosvlaiion en-hances oxygen radical induced modifications and decreases aceylhvdro 1 -ase activiy of human low densiy lipoprotein.Basic Res Cardiol,1997,92(6):96
[88]Ishii H,Jirousek MR,Koya D.Amerlioration of vascular dysfunctions in diabetic rats by an oral PKC- β inhibitor Science,1996,272(5262):729
[89]Rosenherv M,Correct ILOLLar R.PaLhohenesis and risk factor for diahelic Nephropalhv.In:Jacohson HR,Striker GE,Klahr S.The principle and practice of Nephrology.ST lowis MoshY,1995:330
[90]Kimura M.Platelet protein kinase C(PKC) isoform activity in NIDDM patients complicated with retinopathy and nephropathy.Diabetes,1998,47(Suppl1):440
[91]秦岭,陈江华.骨桥蛋白在肾脏病领域的研究进展.国际泌尿系统杂志,2006,26(1):129-130
[92]吴永贵,林善锬,周江华,等.苯那普利对糖尿病大鼠。肾小管间质损伤的保护作用及机制[J].中华内分泌代谢杂志,2003,19(5):406-407
[93]郭啸华,刘志红,李恒,等.高糖高脂饮食诱导的2型糖尿病大鼠模型及其肾病特点[J].中国糖尿病杂志,2002,10(5):290-294
[94]Forbes JM,Cooper ME,Thallas V,et al.Reduction of the accumulate -on of advanced glycation end products by ACE inhibition in exper -imental diabetic nephropathy[J].Diabetes 2002,51(11):3274-3282
[95]Mumtaz FH,Dashwood MR,Khan MA,et al.Down-regulation of nitric oxide synthase in the diabetic rabbit kidney:potential relevance to the early pathogenesis of diabetic nephropathy[J].Curt Med Res Opin,2004,20(1):1-6
[96]王宗保,袁中华,余坚,等.诱发糖尿病饲料致新西兰兔动脉粥样硬化时血糖、血胰岛素和肝、肾、胰组织结构的变化[J].中国动脉硬化杂志,2001,9(5):391-393
[97]Wei P,Lane PH,Lane JT,et al.Glomerular structural and functional changes in a high-fat diet mouse model of early-stage type 2 diabetes[J].Diabetologia,2004,47(9):1541-1549
[98]Yokozawa T,Nakagawa T,Wakaki K,et al.Animal model of diabetic nephropathy[J].Exp Toxicol Pathol,2001,53(5):359-363
[99]郑学民,林毅,乔文军,等.糖尿病大鼠早期肾病模型的实验研究[J].中国实验动物学杂志,2002:,12(5):288-291
[100]Maeda M,Yabuki A,Suzuki S,et al.Renal lesions in spontaneous insulindependent diabetes mellitus in the nonobese diabetic mouse:acute phase of diabetes[J].Vet Pathol,2003,40(2):187- 195.
[101 ]Cohen MP, Sharma K, Guo J, et al. The renal TGF-beta system in the db/db mouse model of diabetic nephropathy [J]. Exp Nephrol, 1998,6(3):226-233
[102] Sato N, Komatsu K, Kurumatani H. Late onset of diabetic nephro -pathy in spontaneously diabetic GK rats [J]. Am J Nephrol, 2003,23(5):334-342
[103]Nobrega MA, Fleming S, Roman RJ, et al. Initial characterization of a rat model of diabetic nephropathy [J]. Diabetes,2004,53:735-742
[104] Schafer S, Linz W, Bube A, et al. Vasopeptidase inhibition prevents nephropa-thy in Zucker diabetic fatty rats [J].CardiovascRes,2003,60(2):447-454
[105]Yagi K, Kim S, Wanibuchi H. Characteristics of diabetes, blood pressure, and cardiac and renal complications in Otsuka Long-Evans Tokushima Fattyrats [J].Hypertension,1997,29(3):728-735
[106]Pavan MV, Ghin B, Castro M, et al. Prevention of hypertension atten -uates albuminuria and renal expression of fibronectin in diabetic spont -aneously hypertensive rats [J]. AmJNephrol,2003,23(6):422-428
[107] Gross ML, Ritz E, Schoof A, et al. Comparison of renal morphology in the streptozotocin and the SHR/N-cp models of diabetes [J]. Lab Invest,2004,84:452-464
[108] Raz I, Wexler I, Weiss O, et al. Role of insulin and the IGF system in renal hypertrophy in diabetic Psammomys obesus (sand rat) [J] .Nephrol Dial Transplant, 2003,18(7):1293-1298
[109] Cusumano AM, Bodkin NL, Hansen BC, et al. Glomerular hyper- trophy is associated with hyperinsulinemia and precedes overt diabetes in aging rhesus monkeys [J]. Am J Kidney Dis, 2002,40 (5):1075-1085
[110] Kelly DJ, Wilkinson-Berka JL, Allen TJ, et al. A new model of diabetic nephropathy with progressive renal impairment in the transg -enic (mRen-2)27 rat (TGR)[J]. Kidney Int,1998,54:343-352
[111] Wogensen L, Nielsen CB, Hjorth P, et al. Under control of the renal promoter,locally produced transforming growth factor-beta1 induces accumulation of glomerular extracellular matrix in transgenic mice [J]. Diabetes, 1999, 48(1):182-192
[112]Yamamoto Y,Kato I,Doi T,et al.Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice[J].JClin Invest,2001,108:261-268
[113]Trachtman H,Futterweit S,Pine E,et al.Chronic diabetic nephrop -athy:role of inducible nitric oxide synthase[J].Pediatr Nephrol,2002,17(1):20-29
[114]Ng DP,Hardy CL,Bums WC,et al.Prevention of diabetes-induced albuminuria in transgenic rats overexpressing human aldose reductase[J].Endocrine,2002,18(1):47-56
[115]Doublier S,Seurin D,Fouqueray B,et al.Glomerulosclerosis in mice transgenic for human insulin-like growth factor-binding protein-1[J].Kidneylnt,2000,57:2299-2307
[116]Pugliese G;Pricci F,Iacobini C,et al.Accelerated diabetic glomerulo-pathy in galectin-3/AGE receptor 3 knockout mice[J].FASEB,2001,15:2471-2479
[117]宏初,呈恒莲,刘国辉,等.前列腺素E1与福辛普利联合治疗糖尿病肾病疗效分析[J].中国实用内科杂志,2004,1(9):538-540
[118]周晓慧,常永丽.苯那普利川芎嗪联合治疗糖尿病肾病疗效观察[J].内蒙古医学院学报,2006,2(28):117
[119]王鹏虎,宋留生,王晓青.苯那普利治疗早期糖尿病肾病疗效观察[J].中国误诊学杂志.2006,6(17):3345-3346
[120]北京制药工业研究所.川芎嗪有效成分的研究.川芎嗪的提取、分离和结构鉴定[J].中华医学杂志,1977,57(7):420.
[121]北京制药工业研究所.川芎嗪Ⅰ号生物碱的结构鉴定及合成[J].中草药通讯,1977,4:464.
[122]北京制药工业研究所.川芎嗪有效成分的研究-川芎嗪的药理研究[J].中华医学杂志,1977,57:464.
[123]王玉良.川芎嗪对心血管组织的药理和电生理作用-一种新的钙拮抗剂[J].中西医结合杂志,1985,5(5):291.
[124]赵秀珍.川芎嗪针剂对早期糖尿病肾病疗效观察.医药论坛杂志,2004,25(6):31-33
[125]曾健英,罗正茂,张建林.川芎嗪治疗糖尿病肾病68例.广东医学, 2005,26(7):1004-1005
[126]崔哲,陈馥,谷素洁,等.川芎嗪对老年糖尿病肾病病人肾功能及血脂的影响.人民军医,2006,49(4):190-191
[127]赵秀珍.川芎嗪针剂对早期糖尿病肾病疗效观察[J].医药论坛,2004;25(6):31-32
[128]阮颖新,李丽英,陈云波,等.1型糖尿病与2型糖尿病血脂变化比较[J].哈尔滨医科大学学报,2004;38(1):94-95
[129]杨巧芝,吕学云,于爱菊.川芎嗪对肾病综合征血脂及载脂蛋白的变化的临床研究[J].中国当代儿科杂志,2002;4(6):491-492
[130]Bianchis,Bigazzi R,Canpese V Micralbuminuria in essential hypertension[J].Am J Kidney Dis,1999;34:973
[131]王力宁,糖尿病肾病的非血液净化治疗[J].肾脏病与透析肾移植杂志,2003,12(5):443
[132]梁锋,赵敏毅.洛汀新和葛根素治疗糖尿病肾病的临床疗效[J].实用医技杂志,2006,13(4):544
[133]陈淑娇,郑京.ACEI、ARB阻止糖尿病肾病发展的机制[J].现代实用医学,2004,16(12):741
[134]熊燕,贾汝汉.肾素-血管紧张素系统在糖尿病肾病发病机制中的新认识.中国中西医结合肾病杂志,2004,5(9):553-555
[135]Li C,Yana CW.Park CW.et al.Long-term trealment with ramipril auenuales renal osleoponlin expression in diahelic rats.Kidney Inl,2003,63(2):454-463
[136]邢淑丽,郑君芙,黄文政.单侧肾切除STZ诱导糖尿病肾病大鼠动物模型研究.中国中医急症杂志,2006;(15)6:643-644
[137]顾明,邵凤民.肾小管间质纤维化机制的研究进展.医药论坛杂志,2005,26:(5)70-73
[138]谢席胜.糖尿病肾病单味中药研究进展[J].中医药研究,2002,18(6):47-48
[139]邵倩,陈福琴.川芎嗪在糖尿病肾病中的应用及其机制研究.中国中西医结合肾病杂志,2002,3(12):739-741
[140]于淼.糖尿病肾病中药复方实验研究进展[J].长春中医学院学报,2004,20(1):57-59
[14]林兰,倪青,高齐健,等.糖微康胶囊治疗糖尿病肾病的临床观察[J].中国中西医结合杂志,2000,20(11):811-814
[142]冯建春,倪青.糖肾胶囊治疗糖尿病肾病的临床研究[J].中国中西医结合杂志,2000,20(3):212-214
[143]宫伟星,姜新国,王俊基,等.糖肾通宝饮治疗早期糖尿病肾病的临床研究[J].山东中医药大学学报,2000,24(2):111-113
[144]翁孝刚,郭永年,王道刚,等.川芎嗪治疗糖尿病慢性并发症.新乡医学院学报;1993,10(3):187.
[145]唐诗伟,朱红倩,晏永慧,等.川芎嗪治疗2型糖尿病肾病38例观察.实用中医药杂志,1999,15(8):3-4
[146]顾碧云,戴晓星,张允亭,等.川芎嗪对糖尿病血液高凝状态的影响[J].中西医结合杂志,1989,9(5):320
[147]吴建平,沈世忠,杨忠民.川芎嗪对肾病综合征肾功能、血脂及血液流变学的影响[J].中华肾脏病杂志,1999,15(3):169
[148]Chiarelli F,Cipollone F,Romano F,et al.Increased circulating nitric oxide in young patients with type 1 dadetes and persistent microal bumiuria relation to glomerular hyperfiltration[J].Diabetes,2000,49(7):1258-1263
[149]熊旭明,梁剑波,潘巧红,等.尿视黄醇结合蛋白与糖尿病肾病.中华肾脏病杂志.1997,13(4):215
[150]杨沛,陈伟,姚春燕.糖尿病肾病的早期诊断.中国现代医学杂志.2002,3(5):48-50
[151]陈海英,沈稚舟.2型糖尿病病人微量白蛋白的影响因素.中国实验诊断杂志.1998,2(1):18-21
[152]孙蓉.NAG、RBP检测对早期糖尿病肾病的诊断价值.衡阳医学院报,2000,5(3):282-283
[153]Bemard Am,Vyskail AA,Mahieu PX,et al.Assessment of urinary retindbinding protein as an index of proximal tubular injury.Cli Chem,1987,33:775
[154]朴春丽,南红梅.从炎症发病机制探讨中医治疗糖尿病肾病的思路与方法.中国中西医结合杂志,2005,25(4)365-367
[155]Rosenbery M,Correa Rottar R.Patbhgenesis and risk factor for diabetic nepbropatby[J].Kidney Int,1995,46:272- 278
[156]LiC,Yang Park renalosteopont in expression etal.Long-term treatment with ramipril attenuates in diabetic rats.Kidney Int,2003,63:454-- 463
[157]Abdel-Wahab N,Yevdokimova N,Weston BS etal.Role of connective tissue growth factor in the pathogenesis of diabetic nephropathy.BiochemJ,2001;359(1):77-87
[158]张卫平.浅谈活血化瘀法在糖尿病肾病治疗中的运用.实用中医药杂志,2003,19(5);268
[159]Minervini R,PanichiV,Vigano L,et al.Cellular expression of lymphocyte function-associated antigen-1 and intercellular adhesion molecule-1 in normal kidney structures and in renal cancer.Possible significance in immune response and in the clinicopathological correlation.Eur Urol.1994;26(1):103- 106.
[160]Heicappell R,Podlinski J,Buszello H,et al.Cell surface expression and serum levels of intercellular adhesion molecule-1 in renal cell carcinoma.Urol Res.1994;22(1):9-15.
[161]Baer PC,Scherberich JE,Bereiter-Hahn J,et al.Induction of RANTES,HLA-DR,and intercellular adhesion molecule-1 on highly purified distal tubular cells from human kidney.Transplantation.2000 Jun 15;69(11):2456-2459.
[162]Shappell SB,Mendoza LH,Gurpinar T,et al.Expression of adhesion molecules in kidney with experimental chronic obstructive uropathy:the pathogenic role of ICAM-1 and VCAM-1.Nephron.2000 Jun;85(2):156-166.
[163]Chow J,Hartley RB,Jagger C,et al.ICAM-1 expression in renal disease.[J].Clin Pathol.1992 Oct;45(10):880-884.
[164]Kuroiwa T,Lee EG.Cellular interactions in the pathogenesis of lupus nephritis:the role of T cells and macrophages in the amplification of the inflammatory process in the kidney.Lupus.1998;7(9):597-603.
[165]刘颖慧,李红.TNF-α与糖尿病肾病[J].国外医学内分泌学分册,2002,22(4):253-256.
[166]Hellmich B,Schellner M,Schatz H,et al.[J].Metabolism,2000,49(3):353- 359
[167]Navarro JF,Mora C,Rivero A,et al.[J].Am J Kidney Dis,1999,33(3):458-463
[168]钱玉润,胡春,周令芳.糖尿病肾病血TNF-α浓度的探讨[J].上海第二医科大学学报,2004,25(2):206-207.
[169]Hasegawa G;Nakano K,Sawada M,et al.Possible role of necrosis factor and interleukin-1 in the development of diabetic nephropathy[J].Kidney Int,1991,40(6):1007-1012.
[170]Hirano T,Aldra S,Taga T,et al.Biological and clinical aspects of interleukin 6.Immunol Today,1990,11(12):443
[171]Shikano M,Sobajima H,Yoshikawa H,et al.[J]Nephron,2000,85(1):81-85
[172]Suzuki D,Miyazaki M,Naka R,et al.In situ hybridization of intedeukin 6 in diabetic nephropathy.Diabetes,1995,44(10):1233
[173]Shikano M,Sobajima H,Yoshikawa H,et al.Usefulness of a highly sensitive urinary and serum IL-6 assay in patients with diabetic nephropathy.Nephron,2000,85(1):81
[174]Kitamura A,Hasegawa G;Obayashi H,et al.Interleukin-6 poly- morphism (-634C/G) in the promoter region and the progression of diabetic nephropathy in Type 2 diabetes.Diabetic Medicine,2002,19(12):1000
[175]Morohoshi M,Fujisawa K,Uchimura I,et al.The effect of glucose and advanced glycosylation end products on IL-6 production by human monocytes.Ann NY Acad Sci,1995,748(1):562
[176]Takagi M,Kasayama S,Yamamoto T,et al.Advanced glycation endproducts stimulate interleukin-6 production by human bone-derived cells.J Bone Miner Res,1997,12(3):439
[177]Bursten S,Harris W.Interleukin-1 stimulates phosphatidic acid mediated phospholipase D activity in human messangial.Am J Physiol,1994,266(4):C1093
[178]张永钢,韩梅,温进坤.骨桥蛋白的病理功能.中国学杂志,2005,2(25):230
[179]Nagasaki synthesis Ischimura E,Shioi A,etal.Osteopontin gene expression and proteinculturedratmessangialcells.Biochem Biophys Res Commun,1997,233:812-815.
[180]Hynes RO.Integrins:a family of cell surface receptor.Cell,1987,48(3):549.
[181]Woessner JF.The matrix metalloproteinase family.In:Parks WC, Mecham RP,ed.Matrix Metalloproteinases.San Diego:Calif:Academic Press,1998,1(2):13
[182]王银娜 李荣芬.骨桥蛋白与肾脏病.国外医学·生理、病理科学与临床分册,2003,23(5):504-506
[183]Gilbert RE,Cooper ME.The tubulointer stitium in progressive diabetic kidney disease:more than an aftermath of glomerular injuryKidney Int,1999,56(5):1627-1637
[184]Guo H,Cai CQ,Schroeder RA,et al.Osteoyontin is a negative feedback regulator of nitric oxide synthesis in marine macrophages.Jurnunol,2001,166:1079-1086
[185]Verhulst A,Persy VP,Van Rompay AR,et al.Osteopontin synthesis and localiza -tionalong the Human Nephron.J Am Soc Nephrol,2002,45(13):1210-1218
[186]Abdel-Wahab N,Yevdokimova N,Weston BS etal.Roleof connective tissue growth factor in the pathogenesis of diabetic nephropathy.Biochem J,2001,359(1):77-87.
[187]Junaid A,Amara FM.Osteopontin:correlation with interstitial fibrosis in human diabetic kidney and PI3-kinase-mediated enhancement of expression by glucose in human proximal tubular epithelial cells.J Histopathol,2004,44:136-145
[188]李君,董吉祥.2型糖尿病患者糖尿病肾病危险因素分析.苏州大学学报医学版.2005,25(2):273-274
[189]Kelly DJ,T,Wilkinson-Berka,JL,Bicardo SD,et al.Progressin of t nhulo interstitialinjury by osteopontir induced neplhropathy of transgenicmacrophage 27rats.Nephrol Dial Transplant,2002,17:985-991
[1]Phillips AO,Steadman R.Diabetic nephropathy:the central role of renal proximal tubular cells in tubulointerstitial injury.Histol Histopathol 2002,17(1):247-52
[2]Tsilibary EC.Microvascular basement membranes in diabetes mellitus J Pathol,2003,200(4):53?-46
[3]邝安.糖尿病在中国.长沙:湖南科技出版社,1989,277-278
[4]Li Ls.End-stage renal disease in China[J].Kidney Int,1996,49:287.
[5]Raij L.Recommendation for the management of special populations:renal disease in diabetes.Am J Hypertens,2003,16(11Pt2):46-49
[6]佟之复,李宁华,苗俊梅,等.2型糖尿病肾病流行病学研究进展[J].中国老年学杂志,2001,21(3):241-243.
[7]王竹兰,冯根宝,王燕燕,等.642例糖尿病患者肾脏病变的调查及临床分析[J].中国糖尿病杂志,1995,3(3):7.
[8]Anderson AR,et al.Diabetic nephropathy in type 1(insulin-dependent)diabetes:An epidemiological study.Diabetologia,1983,23 B496
[9]钟学礼.临床糖尿病学.上海:上海科技出版社,1987,271-273
[10]Li JM,Shah AM.ROS generation by nonphagocytic NADPH oxidase:potential relevance in diabetic nephropathy[J].J AmSoc Nephrol,2003 Aug,14(8 Suppl 3):S221
[11]BaricosWH,Cortez SL,el-Dahr SS,et al.ECM degradation by cultured human mesangial cells is mediated by a PA/plasmin/MMP-2 cascade[J]Kidney Int,1995,47(4):1039
[12]Chen S,Jim B,et al.Diabetic nephropathy and transforming growth factor-beta:transforming our view of glomerulosclerosis and fibrosis build-up.Ziyadeh FN[J].Semin Nephrol,2003 Nov,23(6):532
[13]Ziyadeh FN.Mediators of diabetic renal disease:the case for tgf-Beta as the major mediator[J].J Am Soc Nephrol,2004 Jan,15Suppl 1:S55
[14]Hodgkinson AD,Millward BA,Demaine AG.Polymorphism of the glucose transporter(GLUT1) gene are associated with diabetic nephropathy[J].Kiney Int,2001,59(3),985
[15]Abdel-Wahab N,Weston BS,et al.Connective tissue growth factor and regulation of the mesangial cell cycle:role in cellular hypertrophy [J].J Am Soc Nephrol,2002,13(10):2437
[16]Okada S,Shikata K,et al.Intercellular adhesion molecule-1-deficient mice are resistant against renal injury after induction of diabetes[J].Diabetes,2003 Oct,52(10):2586
[17]Forbes JM,Cooper ME,et al.Role of advanced glycation end products in diabetic nephropathy[J].J Am Soc Nephrol,2003,14(8 Supp 13):S254
[18]Omoto S,Nomura S,et al.Significance of platelet-derived microparticles and activated platelets in diabetic nephropathy[J].Nephron,1999,81(3):271
[19]郭赛珊.治疗糖尿病肾病的经验体会.中国中西医结合杂志,1996,16(1):3
[20]吕仁和,时振声.糖尿病肾病的中医诊治[J].北京中医,1989,8(2):8-10
[21]林兰.中西医结合糖尿病学.北京:中国医药科技出版社.1999:394
[22]熊曼琪,苗理平.加味桃核承气汤对糖尿病鼠肾超微结构的影响[J].中国医药学报,1990,5(5):25-27
[23]张泽生,袁遵守,杨新军,等.益肾扶脾化瘀降浊法治疗糖尿病肾病64例临床观察.新中医.2001,33(11):36
[24]林兰.糖尿病中西医结合论治[M].北京:北京科学技术出版社1992,229.
[25]高彦彬,易京红.糖肾宁治疗糖尿病肾病的临床研究.中医杂志,1991,32(7):31
[26]苏小惠.中西医结合治疗糖尿病肾病40例临床观察.辽宁中医杂志.2006,33(1):92-93
[27]王国芝,张莉,屈云.糖尿病肾病的中西医结合治疗的临床研究[J].现代中医药,2003,(4):36-38
[28]张焱.中西医结合治疗糖尿病肾病30例的临床观察.生临床和实验医学杂志.2006,5(4):402-403
[29]陈望善,杨玉霞,李华.中西医结合治疗糖尿病肾病的临床观察.湖北中医杂志.2004,26(12):9-10
[30]胡宝峰,李秋英,任小强,等.补阳还五汤加味治疗早期糖尿病肾病56例.陕西中医,2005,26(12):1281-1282
[31]石焕玉,朱晓勇.大柴胡汤加减治疗Ⅳ期糖尿病肾病32例疗效观察.中医杂志.2004,45(3):195-196
[32]吴钧俊.济生肾气丸加味治疗临床期糖尿病肾病40例疗效观察.中药新药与临床药理.2003,14(3):205-206
[33]陈辉崇,刘柏炎,加味地黄汤治疗早期糖尿病肾病32例,湖南中医杂志.2004,第20(2):36-37
[34]林楠,宋王宣,薛丽.通心络胶囊治疗糖尿病肾病疗效观察.中国误诊学杂志.2005,5(9):1663-1664
[35]宋晓燕,陈蔷,齐晓燕.六味地黄丸对早期糖尿病肾病患者红细胞醛糖还原酶活性的影响.中国中西医结合杂志.2004,24(12):1087-1090
[36]陈弼沧,吴秋英.血府逐瘀口服液治疗糖尿病肾病的临床观察.吉林中医药.2003,23(1):15-16
[37]许建秦,朱海慧,阿魏酸钠配合降糖药治疗糖尿病肾病22例,陕西中医.2005,26(8):751-753
[38]尹红梅.川芎嗪与山莨菪碱治疗糖尿病肾病40例.临床荟萃.2000,15(12):553-554
[39]黄各宁,陈积优,张镁元.灯盏花素注射液对糖尿病肾病血液流变学影响的临床研究.新.2006,38(3):34-35
[40]杨益芳.葛根素注射液治疗50例糖尿病肾病的疗效观察.泸州医学院学报.2003,26(1):44-45
[41]曹骥翔,唐新玉,丁亮,等.黄芪、生脉注射液联合苯那普利治疗糖尿病肾病32例疗效观察.湖南中医药导报.2002,8(10):596-597
[41]杨燕,邸阜生,李坤.静黄芪丹参注射液与开博通联合应用治疗糖尿病肾病. 临床观察天津医科大学学报.2000,6(1):79-81
[42]史伟,唐爱华,吴金玉,等.水蛭注射液治疗糖尿病肾病57例疗效观察.新中医.2006,38(3):38-40
[43]马为,唐桂军,郭泉滢.杏丁注射液治疗糖尿病肾病52例.中医研究.2004,17(2):31-32
[44]刘香春.中药灌肠法治疗糖尿病肾病肾功能不全30例.四川中医.2006,24(4):68-69
[45]王秀霞,李富英.中药灌肠合灸神厥穴对糖尿病晚期肾病的影响.山东医药.2006,46(28):72
[1].Yokozawa T,Nakagawa T,Wakaki K,et al.Animal model of diabetic nephropathy[J].Exp Toxicol Pathol,2001,53(5):359-363
[2]郑学民,林毅,乔文军,等.糖尿病大鼠早期肾病模型的实验研究[J].中国实验动物学杂志,2002,12(5):288-291
[3]Maeda M,Yabuki A,Suzuki S,et al.Renal lesions in spontaneous insulin-dependent diabetes mellitus in the nonobese diabetic mouse:acute phase of diabetes[J].Vet Pathol,2003,40(2):187-195
[4]Cohen MP,Sharma K,Guo J,et al.The renal TGF-beta system in the db/db mouse model of diabetic nephropathy[J].Exp Nephrol,1998,6(3):226-233
[5]吴永贵,林善锬,周江华,等.苯那普利对糖尿病大鼠肾小管间质损伤的保护作用及机制[J].中华内分泌代谢杂志,2003,19(5):406-407
[6]Sato N,Komatsu K,Kurumatani H.Late onset of diabetic nephropathy in spontaneously diabetic GK rats[J].Am J Nephrol,2003,23(5):334-342
[7]Nobrega MA,Fleming S,Roman RJ,et al.Initial characterization of a rat model of diabetic nephropathy[J].Diabetes,2004,53:735-742
[8]Schafer S,Linz W,Bube A,et al.Vasopeptidase inhibition prevents nephropathy in Zucker diabetic fatty rats[J].CardiovascRes,2003,60(2):447-454
[9]Yagi K,Kim S,Wanibuchi H.Characteristics of diabetes,blood pressure,and cardiac and renal complications in Otsuka Long-Evans Tokushima Fattyrats[J].Hypertension,1997,29(3):728-735
[10]Pavan MV,Ghin B,Castro M,et al.Prevention of hypertension atten -uates albuminuria and renal expression of fibronectin in diabetic spont -aneously hypertensive rats[J].AmJNephrol,2003,23(6):422-428
[11]Gross ML,Ritz E,Schoof A,et al.Comparison of renal morphology in the streptozotocin and the SHR/N-cp models of diabetes[J].Lab Invest, 2004,84:452-464
[12] Raz I, Wexler I, Weiss O, et al. Role of insulin and the IGF system In renal hypertrophy in diabetic Psammomys obesus (sand rat) [J].Nephrol Dial Transplant, 2003,18(7):1293-1298
[13] Cusumano AM, Bodkin NL, Hansen BC, et al. Glomerular hyper- trophy is associated with hyperinsulinemia and precedes overt diabetes in aging rhesus monkeys [J]. Am J Kidney Dis, 2002, 40 (5):1075-1085
[14] Kelly DJ, Wilkinson-Berka JL, Allen TJ, et al. A new model of diabetic nephropathy with progressive renal impairment in the transg -enic (mRen-2)27 rat (TGR)[J]. Kidney Int, 1998, 54:343-352
[15] Wogensen L, Nielsen CB, Hjorth P, et al. Under control of the renal promoter, locally produced transforming growth factor-betal induces accumulation of glomerular extracellular matrix in transgenic mice [J]. Diabetes, 1999, 48(1):182-192
[16]Yamamoto Y, Kato I, Doi T, et al. Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice [J]. J Clin Invest, 2001,108:261-268
[17] Trachtman H, Futterweit S, Pine E, et al. Chronic diabetic nephrop-athy: role of inducible nitric oxide synthase [J]. Pediatr Nephrol,2002,17(1): 20-29
[18]Ng DP, Hardy CL, Burns WC, et al. Prevention of diabetes-induced albuminuria in transgenic rats overexpressing human aldose reductase [J]. Endocrine, 2002, 18(1): 47-56
[19]Doublier S, Seurin D, Fouqueray B, et al. Glomerulosclerosis in mice transgenic for human insulin-like growth factor-binding protein-1 [J]. KidneyInt, 2000,57:2299-2307
[20] Pugliese G, Pricci F, Iacobini C, et al. Accelerated diabetic glomerulopathy in galectin-3/AGE receptor 3 knockout mice [J]. FASEB,2001, 15:2471-2479
[21]Daniel PE.Diabetes mellitus(M).5th ed.Beijing:Science Press,2000.971-1008
[22]Jean DW,Daniel WF,Henry MK,et al.Williams textbook of endocrine -fogy(M) 9th ed.Bei.jing:Science Press,2001,1014 -1022
[23]孙建红,何戎华,任传路.虫草制剂和开博通对糖尿病大鼠肾脏功能和形态影响的对比研究.徐州医学院学报,2000,20(6):450-453
[24]张振忠,豆小妮,赵宏波,等.参芪糖肾安胶囊治疗糖尿病肾病的动物实验研究.现代中医药,2007,27(3):69-71
[25]艾智华,蔡红卫,张忠辉.大黄酸治疗大鼠糖尿病肾病的实验研究.第三军医大学学报,2004,26(4):304-306
[26]柴可夫,柴瑞.糖肾汤对糖尿病大鼠肾脏保护作用的实验研究.中医药学刊,2005,23(9):1551-1552
[27]李佑生,王文健,马宇滢,等.复方丹参滴丸防治大鼠早期糖尿病肾脏损害的研究.中成药,2007,(1):40-44
[28]屈智慧,毕黎矛,邹洪斌.长春新碱治疗糖尿病肾病大鼠的实验研究中国生物制品学杂志,2004,17(3):61-65
[29]王瑞良,张洪梅,苏青.苯那普利对糖尿病大鼠肾组织RAGE表达的影响.上海交通大学学报(医学版),2007,27(2):182-184
[30]姜宝红,苏环德,徐峰,等.Doxium及Diamicron联合应用对大鼠糖尿病肾病防治的研究.黑龙江医学,2006,30(1):10-13
[31]焦秀敏,刘宽芝.缬沙坦对2型糖尿病大鼠肾脏保护作用的研究.中国糖尿病杂志,2003,11(5):337-340
[32]李晔,甘卫华,王晓颖,等.5-羟色胺2A受体拮抗剂减轻糖尿病肾病的实验研究.肾脏病与透析肾移植杂志,2002,11(5):401-406
[33]张莹雯,谢丹,杜光,等.归芪方合苯那普利对糖尿病大鼠肾组织转化生长因子β1的影响.中国中西医结合杂志,2005年6月第25卷基础理论研究特集86-90
[34]朱国茹,石岩,马丽佳.糖肾保煎剂和雷米普利对糖尿病大鼠肾脏保护作用的对比实验.中国中医药信息杂志,2005,12(1):30-32
[2]Tsilibary EC.Microvascular basement membranes in diabetes mellitus.J Pathol,2003,200(4):537-46.
[3]邝安.糖尿病在中国.长沙:湖南科技出版社,1989,277-278
[4]Li Ls.End-stage renal disease in China[J].Kidney Int,1996,49:287.
[5]Raij L.Recommendation for the management of special populations:renal disease in diabetes.Am J Hypertens,2003,16(11Pt2):46-49
[6]佟之复,李宁华,苗俊梅等.2型糖尿病肾病流行病学研究进展[J].中国老年学杂志,2001,21(3):241-243.
[7]王竹兰,冯根宝,王燕燕,等.642例糖尿病患者肾脏病变的调查及临床分析[J].中国糖尿病杂志,1995,3(3):7.
[8]Anderson AR,et al.Diabetic nephropathy in type 1(insulin-dependent) diabetes:An epidemiological study.Diabetologia,1983,23 B496
[9]钟学礼.临床糖尿病学.上海:上海科技出版社.1987,271-273
[10]张永钢,韩梅,温进坤.骨桥蛋白的病理功能冲国老年学杂志,2005;25:230-231
[11]Bemard Am,Vyskail AA,Mahieu PX,et al.Assessment of urinary retindbinding protein as an index of proximal tubular injury.Cli Chem,1987,33:775
[12]Wolf G,Ziyadeh FN,Stahl RA.Angiotensin Ⅱ stimulates expression of transforming growth factor beta receptor type Ⅱ in cultured mouse proximal tubular cells[J].JMohned,1999,77(5):556-564
[13]苏小惠.中西医结合治疗糖尿病肾病40例临床观察.辽宁中医杂志.2006,33(1):92-93
[14]林楠,宋王宣,薛丽.通心络胶囊治疗糖尿病肾病疗效观察.中国误诊学杂志.2005,5(9):1663-1664
[15]谢席胜,黄宗文.中西医结合治疗糖尿病的优势评价.中国临床康复,2006,10(35):151-154
[16]吕仁和.糖尿病及其并发症中西医诊治学[M].北京:人民卫生出版社,2001,328
[17]倪青.糖尿病。肾病的中医药研究思路与方法[J].中国医药学报,1998,13(4):60-62
[18]倪青.活血化瘀法治疗糖尿病肾病42例.南京中医药大学学报,2003,19(6):380
[19]魏连波.糖尿病肾病病因病机的探讨.福建中医药,2003,34(2:46-47
[20]曲晓璐,陈大舜,姚欣艳,等.1718例2型糖尿病患者糖尿病肾病发病率及其中医证型分布特点.中国中西医结合肾病杂志,2003,4(12):713
[21]成玉斌,罗仁,胡志飞,等.糖尿病肾病中医辨证分型荟萃分析.中国中医基础医学杂志,2000,6(5):49
[22]杨霓芝,王立新,廖平平.248例糖尿病肾病患者分期辨证分析.广州中医药大学学报,1998,15(4):260
[23]杨霓芝,李芳,徐大基,等.糖尿病肾病分期辨证治疗的探讨.辽宁中医杂志,1999,26(1):16
[24]陈辉,汤水福,赵萍.活血化瘀法治疗早期糖尿病肾病及其对肾血流参数的影响[J].中国中西医结合肾病杂志.2005,6(1):31
[25]郭赛珊.治疗糖尿病肾病的经验体会.中国中西医结合杂志,1996,16(1):3
[26]吕仁和,时振声.糖尿病肾病的中医诊治[J].北京中医,1989,8(2):8-10.
[27]林兰.中西医结合糖尿病学.北京:中国医药科技出版社,1999:394
[28]熊曼琪,苗理平.加味桃核承气汤对糖尿病鼠肾超微结构的影响[J].中国医药学报,1990,5(5):25-27.
[29]张泽生,袁遵守,杨新军,等.益肾扶脾化瘀降浊法治疗糖尿病肾病64例临床观察.新中医,2001,33(11):36
[30]林兰.糖尿病中西医结合论治[M].北京:北京科学技术出版社1992,229.
[31]高彦彬,易京红.糖肾宁治疗糖尿病肾病的临床研究.中医杂志,1991,32(7):31
[32]李毅.祝堪予老中医活血化瘀法治疗糖尿病经验[J].山东中医学院报.1986,9(5):27
[33]高彦彬,易京红.中医药辩治糖尿病肾病100例临床分析[J].中医杂志,1991,32(7):31-32
[34]邓权.益肾活血法治疗糖尿病肾病62例[J].浙江中医杂志,1996,31(7):317-318
[35]耿嘉,栗德林.糖尿病肾病病因病机的辩证.首都医药,2005,3:(12):112
[36]吉勤,王清,李桢,等.活血化瘀法改善糖尿病肾病水肿的疗效观察[J].中国中西 医结合肾病杂志,2006,7(2):109
[37]孙树良,郑杨.活血化瘀法治疗糖尿病肾病临床观察[J].辽宁中医学院学报,2006,8(2):84-85
[38]睦书魁,李细贵.从瘀论治糖尿病57例临床观察[J].中国中西医结合杂志,1992,12(1):43.11
[39]耿嘉,栗德林.糖尿病肾病病因病机的辩证.首都医药,2005,3:(12):112
[40]张宗铭.糖尿病瘀血产生的机理、辨证与治疗(J)安徽中医学院学报,1989,(2):53-56
[41]翁维良.糖尿病人”瘀血”的研究(J)中医杂志,1982,1(1):46-48
[42]吴春林.试析糖尿病从瘀论治的理论基础(J).长春中医学院学报,1997,13(4):3
[43]刘冰冰.糖尿病神经病变患者血液流变性与微循环指标分析.中国血液流变学杂志.2000,10(1):47-49
[44]石志芸,等.血栓相关分子标志物在糖尿病血瘀证中的临床意义(J)中医杂志,1999,40(9):554-555
[45]曾庆祥.糖尿病肾病从瘀论治[J].吉林中医药,2001,21(3):14
[46]林兰,倪青,董彦敏.糖尿病肾病中西医结合治疗热点问题述评[J].中西医结合,2000,7:50.
[47]刘新明,刘晓城.糖尿病肾病的发病机制与治疗现状.中国中西医结合肾病杂,2004,5(9):553-554
[48]施赛珠,王倩,董彩云.Ⅱ型糖尿病中瘀血证和益气活血药预防其血管病变的疗效观察.中医杂志,1989,30(6):341
[49]方立成.化瘀养阴汤治疗Ⅱ型糖尿病56例临床观察.湖南中医学院学报,1994,14(2):20
[50]赵淑华,严庆良.糖尿病患者平均血小板体积和高脂变化的研究.中华内分泌代谢杂志,1998,14(1):42
[51]梁晓春,王秀定,张孟仁.糖尿病患者血浆TXB2.6-K-PGFla水平、全血粘度与血瘀证的微血管病的关系.中国中西医结合杂志,1992,12(5):29
[52]Navarro JF,Mora C,MacaM,et al.Inflammationtory parameters are independently associated with urinary albumin in type 2 diabetes mellitus.Am J Kidney Dis,2003,42:53-61.
[53]Anders H J,Vielhauer V,Schlondorff D.Chemokines and chemokine receptors are involved in the resolution or progression of renal disease.Kidney Int,2003,63:401-415.
[54]Mensah-Brown EPK,Obineche EN,Galadad S,et al.Streptozotocin-induced diabetic nephropathy in rats:The role of inflammatory cytokines.CYTOKI NE,2005,31(3):180-190.
[55]Lee SH,Lee TW,Ihrn CG;et al.Genetics of diabetic nephropathy in type 2 DM:candidate gene analysis for the pathogenic role ofinflammation.Nephrology,2005,10:S32-S36.
[56]Navarro JF,Mora C.Role of inflammation in diabetic complications.Nephrology dialysis transplantation,2005,20(12):2601-2604.
[57]Sfakianaki M,Xydakis D,Papadogiannakia A,et al.1 Low-grade inflammation is correlated to diabetic nephropathy in type 2 diabetes mellitus.Diabetologia,2005,48:A375-A376.
[58]李静,李荣山.巨噬细胞在大鼠糖尿病肾病发病机制中的作用.中国中西医结合肾病杂志,2005,6:79-82.
[59]Chow F,Ozols E,Nikolic Paterson DJ,et al.Macrophages in mouse type 2diabetic nephropathy correlation with diabetic state and progression renal injury.Kidney Int,2004,65:116-128.
[60]Sassy-Prigent C,Heudes D,Mandet C,et al.Early glomerular macrophage recruitment in streptozotocin- induced diabetic rats.Diabetes,2000,49:466-475.
[61]Sheu JR,Kan YC,Hunn WC,el al.Mechanisms involved in the anliplalelel aclivilv of T M P in humanplalelels.Thrornh-Res,1997,88(3):259-270
[62]王海松,谢春光.益肾糖泰颗粒对糖尿病大鼠肾脏病变的影响[N].成都中医药大学学报,2000,23(1):49-57
[63]李建生,郑士荣.中药糖肾安队实验性糖尿病大鼠肾脏病变的作用[J]河南中医1995,15(5):282-284
[64]武慧,杜宏武,谢道俊,等.益气养阴活血化淤法为主治疗老年早期糖尿病肾病31例[N].安徽中医学院学报,2001,20(1):16-18
[65]姜春华.活血化瘀研究[M].上海:上海科技出版社,1981,1:341.
[66]Abdel-Wahab N,Weston BS,et al.Connective tissue growth factor and regulation of the mesangial cell cycle:role in cellular hypertrophy[J].J Am Soc Nephrol,2002,13(10):2437.
[67]Okada S,Shikata K,et al.Intercellular adhesion molecule-1-deficient mice are resistant against renal injury after induction of diabetes[J].Diabetes,2003 Oct,52(10):2586.
[68]Forbes JM,Cooper ME,et al.Role of advanced glycation end products in diabetic nephropathy[J].J Am Soc Nephrol,2003,14(8 Supp 13):S254.
[69]Rosenherv M,Correct ROTTar R.PaLhohenesis and risk factor for diahelic Nephropalhv.In Jacohson HR,Striker GE,KlahrS.The principles and practice of Nephroloay.SL Lowis Mos-hv.1995,330
[70]Jones,and Alebowain Phillips.Regulation of renal proximal tubular epithelial cell hyaluronan generation:Implication for diabetic nephropathy.Kidney Int,2000,59(1):1739-1749
[71]Li JM,Shah AM.ROS generation by nonphagocytic NADPH oxidase:potential relevance in diabetic nephropathy[J].J Am Soc Nephrol,2003 Aug,14(8 Suppl 3):S221
[72]Doric A.Warram JH,Krolewski AS Geneticsusceptihilitv Lonephropathv in insulin dependent diabetes:from epidemioloay Lomolecular nenetics.Diabetes/Metabolism Review,1995,11:287
[73]Hotta N.Risk factors for diabetic complications:Abnormality of polyol metabolism[J].Nippon Rinsho,2002,60(Suppl 10):60-66
[74]Yang Q,Kaji R,Takagi T,et al.Abnormal axonal inward rectifier in s treptozocin induced experimental diabetic neuropathy.Brain.2001 Jun,124(Pt6):1149-55
[75]Raj Ds,Choudhury D,Welboume TC,et al.Advanced glycation end products:a Nephrologist's perspective[J].Am J Kidney Dis.2000,35(3):365-380
[76]Boyd-White J,Williams JC.Effect of cross-linking on matrix perm- eability.A model for AGE-modified basement membranes[J].Diabetes.1996,45(3):348-353
[77]Balkan J,Kanbagli O,Mehmetcik G,et al.Increased lipid peroxidation in serum and low-density Lipoproteins associated with aging in humans[J].Int J Vitam Nutr Res.2002,72(5):315-320
[78]Zhou G,Li C,Cai L.Advanced glycation end-products induceconnec tive tissue growth factor-mediated renal fibrosis predomi nantly through transforming growth factor betaindependent path way[J].Am J Pathol,2004,165:2033-2043.
[79]Wolf G,Ziyadeh FN,Stahl RA.Angiotensin Ⅱ stimulates expression of transforming growth factor beta receptor type Ⅱ in cultured mouse proximal tubular cells[J].JMohned,1999,77(5):556-564
[80]Hodgkinson AD,Millward BA,Demaine AG.Polymorphism of the glucose transporter(GLUT1) gene are associated with diabetic nephropathy[J].Kiney Int,2001,59(3),985.
[81]谭燕,杨永年.AEGs在糖尿病慢性并发症中的作用.中国糖尿病杂志,1990,7:292
[82]秦洁,张志利.糖尿病肾病发病机制的研究进展.山西医科大学学报,2002,33(6):576-577
[83]胡伟新,刘志红,黎磊石,等.IgA肾病患者尿自介素6检测的意义.中华肾脏病杂志,1994,10(4):203
[84]Rosenberg M,Correa-Rottar R.Pathogenesis and risk factors for diabetic nephropathy.In:Jacobson HR,Striker GE,Klahr S.The principle and practice of nephrology.Stlowis Mosby,1995:330
[85]Osende JI,Badimon JJ,Fuster V,et al.Blood thrombogenicity in type2diabetes mellitus patients is associated with glycemiccontrol[J].J AM Coll Cardiol,2001,38(5):1307-1312.
[86]Abbou HE.Growth factors and diabetic nephrology:an overview[J].Kidney Int Suppl,1997,60:S3-6
[87]Napolic C,Triaaiani M,Palumbo G,et al.Glvcosvlaiion en-hances oxygen radical induced modifications and decreases aceylhvdro 1 -ase activiy of human low densiy lipoprotein.Basic Res Cardiol,1997,92(6):96
[88]Ishii H,Jirousek MR,Koya D.Amerlioration of vascular dysfunctions in diabetic rats by an oral PKC- β inhibitor Science,1996,272(5262):729
[89]Rosenherv M,Correct ILOLLar R.PaLhohenesis and risk factor for diahelic Nephropalhv.In:Jacohson HR,Striker GE,Klahr S.The principle and practice of Nephrology.ST lowis MoshY,1995:330
[90]Kimura M.Platelet protein kinase C(PKC) isoform activity in NIDDM patients complicated with retinopathy and nephropathy.Diabetes,1998,47(Suppl1):440
[91]秦岭,陈江华.骨桥蛋白在肾脏病领域的研究进展.国际泌尿系统杂志,2006,26(1):129-130
[92]吴永贵,林善锬,周江华,等.苯那普利对糖尿病大鼠。肾小管间质损伤的保护作用及机制[J].中华内分泌代谢杂志,2003,19(5):406-407
[93]郭啸华,刘志红,李恒,等.高糖高脂饮食诱导的2型糖尿病大鼠模型及其肾病特点[J].中国糖尿病杂志,2002,10(5):290-294
[94]Forbes JM,Cooper ME,Thallas V,et al.Reduction of the accumulate -on of advanced glycation end products by ACE inhibition in exper -imental diabetic nephropathy[J].Diabetes 2002,51(11):3274-3282
[95]Mumtaz FH,Dashwood MR,Khan MA,et al.Down-regulation of nitric oxide synthase in the diabetic rabbit kidney:potential relevance to the early pathogenesis of diabetic nephropathy[J].Curt Med Res Opin,2004,20(1):1-6
[96]王宗保,袁中华,余坚,等.诱发糖尿病饲料致新西兰兔动脉粥样硬化时血糖、血胰岛素和肝、肾、胰组织结构的变化[J].中国动脉硬化杂志,2001,9(5):391-393
[97]Wei P,Lane PH,Lane JT,et al.Glomerular structural and functional changes in a high-fat diet mouse model of early-stage type 2 diabetes[J].Diabetologia,2004,47(9):1541-1549
[98]Yokozawa T,Nakagawa T,Wakaki K,et al.Animal model of diabetic nephropathy[J].Exp Toxicol Pathol,2001,53(5):359-363
[99]郑学民,林毅,乔文军,等.糖尿病大鼠早期肾病模型的实验研究[J].中国实验动物学杂志,2002:,12(5):288-291
[100]Maeda M,Yabuki A,Suzuki S,et al.Renal lesions in spontaneous insulindependent diabetes mellitus in the nonobese diabetic mouse:acute phase of diabetes[J].Vet Pathol,2003,40(2):187- 195.
[101 ]Cohen MP, Sharma K, Guo J, et al. The renal TGF-beta system in the db/db mouse model of diabetic nephropathy [J]. Exp Nephrol, 1998,6(3):226-233
[102] Sato N, Komatsu K, Kurumatani H. Late onset of diabetic nephro -pathy in spontaneously diabetic GK rats [J]. Am J Nephrol, 2003,23(5):334-342
[103]Nobrega MA, Fleming S, Roman RJ, et al. Initial characterization of a rat model of diabetic nephropathy [J]. Diabetes,2004,53:735-742
[104] Schafer S, Linz W, Bube A, et al. Vasopeptidase inhibition prevents nephropa-thy in Zucker diabetic fatty rats [J].CardiovascRes,2003,60(2):447-454
[105]Yagi K, Kim S, Wanibuchi H. Characteristics of diabetes, blood pressure, and cardiac and renal complications in Otsuka Long-Evans Tokushima Fattyrats [J].Hypertension,1997,29(3):728-735
[106]Pavan MV, Ghin B, Castro M, et al. Prevention of hypertension atten -uates albuminuria and renal expression of fibronectin in diabetic spont -aneously hypertensive rats [J]. AmJNephrol,2003,23(6):422-428
[107] Gross ML, Ritz E, Schoof A, et al. Comparison of renal morphology in the streptozotocin and the SHR/N-cp models of diabetes [J]. Lab Invest,2004,84:452-464
[108] Raz I, Wexler I, Weiss O, et al. Role of insulin and the IGF system in renal hypertrophy in diabetic Psammomys obesus (sand rat) [J] .Nephrol Dial Transplant, 2003,18(7):1293-1298
[109] Cusumano AM, Bodkin NL, Hansen BC, et al. Glomerular hyper- trophy is associated with hyperinsulinemia and precedes overt diabetes in aging rhesus monkeys [J]. Am J Kidney Dis, 2002,40 (5):1075-1085
[110] Kelly DJ, Wilkinson-Berka JL, Allen TJ, et al. A new model of diabetic nephropathy with progressive renal impairment in the transg -enic (mRen-2)27 rat (TGR)[J]. Kidney Int,1998,54:343-352
[111] Wogensen L, Nielsen CB, Hjorth P, et al. Under control of the renal promoter,locally produced transforming growth factor-beta1 induces accumulation of glomerular extracellular matrix in transgenic mice [J]. Diabetes, 1999, 48(1):182-192
[112]Yamamoto Y,Kato I,Doi T,et al.Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice[J].JClin Invest,2001,108:261-268
[113]Trachtman H,Futterweit S,Pine E,et al.Chronic diabetic nephrop -athy:role of inducible nitric oxide synthase[J].Pediatr Nephrol,2002,17(1):20-29
[114]Ng DP,Hardy CL,Bums WC,et al.Prevention of diabetes-induced albuminuria in transgenic rats overexpressing human aldose reductase[J].Endocrine,2002,18(1):47-56
[115]Doublier S,Seurin D,Fouqueray B,et al.Glomerulosclerosis in mice transgenic for human insulin-like growth factor-binding protein-1[J].Kidneylnt,2000,57:2299-2307
[116]Pugliese G;Pricci F,Iacobini C,et al.Accelerated diabetic glomerulo-pathy in galectin-3/AGE receptor 3 knockout mice[J].FASEB,2001,15:2471-2479
[117]宏初,呈恒莲,刘国辉,等.前列腺素E1与福辛普利联合治疗糖尿病肾病疗效分析[J].中国实用内科杂志,2004,1(9):538-540
[118]周晓慧,常永丽.苯那普利川芎嗪联合治疗糖尿病肾病疗效观察[J].内蒙古医学院学报,2006,2(28):117
[119]王鹏虎,宋留生,王晓青.苯那普利治疗早期糖尿病肾病疗效观察[J].中国误诊学杂志.2006,6(17):3345-3346
[120]北京制药工业研究所.川芎嗪有效成分的研究.川芎嗪的提取、分离和结构鉴定[J].中华医学杂志,1977,57(7):420.
[121]北京制药工业研究所.川芎嗪Ⅰ号生物碱的结构鉴定及合成[J].中草药通讯,1977,4:464.
[122]北京制药工业研究所.川芎嗪有效成分的研究-川芎嗪的药理研究[J].中华医学杂志,1977,57:464.
[123]王玉良.川芎嗪对心血管组织的药理和电生理作用-一种新的钙拮抗剂[J].中西医结合杂志,1985,5(5):291.
[124]赵秀珍.川芎嗪针剂对早期糖尿病肾病疗效观察.医药论坛杂志,2004,25(6):31-33
[125]曾健英,罗正茂,张建林.川芎嗪治疗糖尿病肾病68例.广东医学, 2005,26(7):1004-1005
[126]崔哲,陈馥,谷素洁,等.川芎嗪对老年糖尿病肾病病人肾功能及血脂的影响.人民军医,2006,49(4):190-191
[127]赵秀珍.川芎嗪针剂对早期糖尿病肾病疗效观察[J].医药论坛,2004;25(6):31-32
[128]阮颖新,李丽英,陈云波,等.1型糖尿病与2型糖尿病血脂变化比较[J].哈尔滨医科大学学报,2004;38(1):94-95
[129]杨巧芝,吕学云,于爱菊.川芎嗪对肾病综合征血脂及载脂蛋白的变化的临床研究[J].中国当代儿科杂志,2002;4(6):491-492
[130]Bianchis,Bigazzi R,Canpese V Micralbuminuria in essential hypertension[J].Am J Kidney Dis,1999;34:973
[131]王力宁,糖尿病肾病的非血液净化治疗[J].肾脏病与透析肾移植杂志,2003,12(5):443
[132]梁锋,赵敏毅.洛汀新和葛根素治疗糖尿病肾病的临床疗效[J].实用医技杂志,2006,13(4):544
[133]陈淑娇,郑京.ACEI、ARB阻止糖尿病肾病发展的机制[J].现代实用医学,2004,16(12):741
[134]熊燕,贾汝汉.肾素-血管紧张素系统在糖尿病肾病发病机制中的新认识.中国中西医结合肾病杂志,2004,5(9):553-555
[135]Li C,Yana CW.Park CW.et al.Long-term trealment with ramipril auenuales renal osleoponlin expression in diahelic rats.Kidney Inl,2003,63(2):454-463
[136]邢淑丽,郑君芙,黄文政.单侧肾切除STZ诱导糖尿病肾病大鼠动物模型研究.中国中医急症杂志,2006;(15)6:643-644
[137]顾明,邵凤民.肾小管间质纤维化机制的研究进展.医药论坛杂志,2005,26:(5)70-73
[138]谢席胜.糖尿病肾病单味中药研究进展[J].中医药研究,2002,18(6):47-48
[139]邵倩,陈福琴.川芎嗪在糖尿病肾病中的应用及其机制研究.中国中西医结合肾病杂志,2002,3(12):739-741
[140]于淼.糖尿病肾病中药复方实验研究进展[J].长春中医学院学报,2004,20(1):57-59
[14]林兰,倪青,高齐健,等.糖微康胶囊治疗糖尿病肾病的临床观察[J].中国中西医结合杂志,2000,20(11):811-814
[142]冯建春,倪青.糖肾胶囊治疗糖尿病肾病的临床研究[J].中国中西医结合杂志,2000,20(3):212-214
[143]宫伟星,姜新国,王俊基,等.糖肾通宝饮治疗早期糖尿病肾病的临床研究[J].山东中医药大学学报,2000,24(2):111-113
[144]翁孝刚,郭永年,王道刚,等.川芎嗪治疗糖尿病慢性并发症.新乡医学院学报;1993,10(3):187.
[145]唐诗伟,朱红倩,晏永慧,等.川芎嗪治疗2型糖尿病肾病38例观察.实用中医药杂志,1999,15(8):3-4
[146]顾碧云,戴晓星,张允亭,等.川芎嗪对糖尿病血液高凝状态的影响[J].中西医结合杂志,1989,9(5):320
[147]吴建平,沈世忠,杨忠民.川芎嗪对肾病综合征肾功能、血脂及血液流变学的影响[J].中华肾脏病杂志,1999,15(3):169
[148]Chiarelli F,Cipollone F,Romano F,et al.Increased circulating nitric oxide in young patients with type 1 dadetes and persistent microal bumiuria relation to glomerular hyperfiltration[J].Diabetes,2000,49(7):1258-1263
[149]熊旭明,梁剑波,潘巧红,等.尿视黄醇结合蛋白与糖尿病肾病.中华肾脏病杂志.1997,13(4):215
[150]杨沛,陈伟,姚春燕.糖尿病肾病的早期诊断.中国现代医学杂志.2002,3(5):48-50
[151]陈海英,沈稚舟.2型糖尿病病人微量白蛋白的影响因素.中国实验诊断杂志.1998,2(1):18-21
[152]孙蓉.NAG、RBP检测对早期糖尿病肾病的诊断价值.衡阳医学院报,2000,5(3):282-283
[153]Bemard Am,Vyskail AA,Mahieu PX,et al.Assessment of urinary retindbinding protein as an index of proximal tubular injury.Cli Chem,1987,33:775
[154]朴春丽,南红梅.从炎症发病机制探讨中医治疗糖尿病肾病的思路与方法.中国中西医结合杂志,2005,25(4)365-367
[155]Rosenbery M,Correa Rottar R.Patbhgenesis and risk factor for diabetic nepbropatby[J].Kidney Int,1995,46:272- 278
[156]LiC,Yang Park renalosteopont in expression etal.Long-term treatment with ramipril attenuates in diabetic rats.Kidney Int,2003,63:454-- 463
[157]Abdel-Wahab N,Yevdokimova N,Weston BS etal.Role of connective tissue growth factor in the pathogenesis of diabetic nephropathy.BiochemJ,2001;359(1):77-87
[158]张卫平.浅谈活血化瘀法在糖尿病肾病治疗中的运用.实用中医药杂志,2003,19(5);268
[159]Minervini R,PanichiV,Vigano L,et al.Cellular expression of lymphocyte function-associated antigen-1 and intercellular adhesion molecule-1 in normal kidney structures and in renal cancer.Possible significance in immune response and in the clinicopathological correlation.Eur Urol.1994;26(1):103- 106.
[160]Heicappell R,Podlinski J,Buszello H,et al.Cell surface expression and serum levels of intercellular adhesion molecule-1 in renal cell carcinoma.Urol Res.1994;22(1):9-15.
[161]Baer PC,Scherberich JE,Bereiter-Hahn J,et al.Induction of RANTES,HLA-DR,and intercellular adhesion molecule-1 on highly purified distal tubular cells from human kidney.Transplantation.2000 Jun 15;69(11):2456-2459.
[162]Shappell SB,Mendoza LH,Gurpinar T,et al.Expression of adhesion molecules in kidney with experimental chronic obstructive uropathy:the pathogenic role of ICAM-1 and VCAM-1.Nephron.2000 Jun;85(2):156-166.
[163]Chow J,Hartley RB,Jagger C,et al.ICAM-1 expression in renal disease.[J].Clin Pathol.1992 Oct;45(10):880-884.
[164]Kuroiwa T,Lee EG.Cellular interactions in the pathogenesis of lupus nephritis:the role of T cells and macrophages in the amplification of the inflammatory process in the kidney.Lupus.1998;7(9):597-603.
[165]刘颖慧,李红.TNF-α与糖尿病肾病[J].国外医学内分泌学分册,2002,22(4):253-256.
[166]Hellmich B,Schellner M,Schatz H,et al.[J].Metabolism,2000,49(3):353- 359
[167]Navarro JF,Mora C,Rivero A,et al.[J].Am J Kidney Dis,1999,33(3):458-463
[168]钱玉润,胡春,周令芳.糖尿病肾病血TNF-α浓度的探讨[J].上海第二医科大学学报,2004,25(2):206-207.
[169]Hasegawa G;Nakano K,Sawada M,et al.Possible role of necrosis factor and interleukin-1 in the development of diabetic nephropathy[J].Kidney Int,1991,40(6):1007-1012.
[170]Hirano T,Aldra S,Taga T,et al.Biological and clinical aspects of interleukin 6.Immunol Today,1990,11(12):443
[171]Shikano M,Sobajima H,Yoshikawa H,et al.[J]Nephron,2000,85(1):81-85
[172]Suzuki D,Miyazaki M,Naka R,et al.In situ hybridization of intedeukin 6 in diabetic nephropathy.Diabetes,1995,44(10):1233
[173]Shikano M,Sobajima H,Yoshikawa H,et al.Usefulness of a highly sensitive urinary and serum IL-6 assay in patients with diabetic nephropathy.Nephron,2000,85(1):81
[174]Kitamura A,Hasegawa G;Obayashi H,et al.Interleukin-6 poly- morphism (-634C/G) in the promoter region and the progression of diabetic nephropathy in Type 2 diabetes.Diabetic Medicine,2002,19(12):1000
[175]Morohoshi M,Fujisawa K,Uchimura I,et al.The effect of glucose and advanced glycosylation end products on IL-6 production by human monocytes.Ann NY Acad Sci,1995,748(1):562
[176]Takagi M,Kasayama S,Yamamoto T,et al.Advanced glycation endproducts stimulate interleukin-6 production by human bone-derived cells.J Bone Miner Res,1997,12(3):439
[177]Bursten S,Harris W.Interleukin-1 stimulates phosphatidic acid mediated phospholipase D activity in human messangial.Am J Physiol,1994,266(4):C1093
[178]张永钢,韩梅,温进坤.骨桥蛋白的病理功能.中国学杂志,2005,2(25):230
[179]Nagasaki synthesis Ischimura E,Shioi A,etal.Osteopontin gene expression and proteinculturedratmessangialcells.Biochem Biophys Res Commun,1997,233:812-815.
[180]Hynes RO.Integrins:a family of cell surface receptor.Cell,1987,48(3):549.
[181]Woessner JF.The matrix metalloproteinase family.In:Parks WC, Mecham RP,ed.Matrix Metalloproteinases.San Diego:Calif:Academic Press,1998,1(2):13
[182]王银娜 李荣芬.骨桥蛋白与肾脏病.国外医学·生理、病理科学与临床分册,2003,23(5):504-506
[183]Gilbert RE,Cooper ME.The tubulointer stitium in progressive diabetic kidney disease:more than an aftermath of glomerular injuryKidney Int,1999,56(5):1627-1637
[184]Guo H,Cai CQ,Schroeder RA,et al.Osteoyontin is a negative feedback regulator of nitric oxide synthesis in marine macrophages.Jurnunol,2001,166:1079-1086
[185]Verhulst A,Persy VP,Van Rompay AR,et al.Osteopontin synthesis and localiza -tionalong the Human Nephron.J Am Soc Nephrol,2002,45(13):1210-1218
[186]Abdel-Wahab N,Yevdokimova N,Weston BS etal.Roleof connective tissue growth factor in the pathogenesis of diabetic nephropathy.Biochem J,2001,359(1):77-87.
[187]Junaid A,Amara FM.Osteopontin:correlation with interstitial fibrosis in human diabetic kidney and PI3-kinase-mediated enhancement of expression by glucose in human proximal tubular epithelial cells.J Histopathol,2004,44:136-145
[188]李君,董吉祥.2型糖尿病患者糖尿病肾病危险因素分析.苏州大学学报医学版.2005,25(2):273-274
[189]Kelly DJ,T,Wilkinson-Berka,JL,Bicardo SD,et al.Progressin of t nhulo interstitialinjury by osteopontir induced neplhropathy of transgenicmacrophage 27rats.Nephrol Dial Transplant,2002,17:985-991
[1]Phillips AO,Steadman R.Diabetic nephropathy:the central role of renal proximal tubular cells in tubulointerstitial injury.Histol Histopathol 2002,17(1):247-52
[2]Tsilibary EC.Microvascular basement membranes in diabetes mellitus J Pathol,2003,200(4):53?-46
[3]邝安.糖尿病在中国.长沙:湖南科技出版社,1989,277-278
[4]Li Ls.End-stage renal disease in China[J].Kidney Int,1996,49:287.
[5]Raij L.Recommendation for the management of special populations:renal disease in diabetes.Am J Hypertens,2003,16(11Pt2):46-49
[6]佟之复,李宁华,苗俊梅,等.2型糖尿病肾病流行病学研究进展[J].中国老年学杂志,2001,21(3):241-243.
[7]王竹兰,冯根宝,王燕燕,等.642例糖尿病患者肾脏病变的调查及临床分析[J].中国糖尿病杂志,1995,3(3):7.
[8]Anderson AR,et al.Diabetic nephropathy in type 1(insulin-dependent)diabetes:An epidemiological study.Diabetologia,1983,23 B496
[9]钟学礼.临床糖尿病学.上海:上海科技出版社,1987,271-273
[10]Li JM,Shah AM.ROS generation by nonphagocytic NADPH oxidase:potential relevance in diabetic nephropathy[J].J AmSoc Nephrol,2003 Aug,14(8 Suppl 3):S221
[11]BaricosWH,Cortez SL,el-Dahr SS,et al.ECM degradation by cultured human mesangial cells is mediated by a PA/plasmin/MMP-2 cascade[J]Kidney Int,1995,47(4):1039
[12]Chen S,Jim B,et al.Diabetic nephropathy and transforming growth factor-beta:transforming our view of glomerulosclerosis and fibrosis build-up.Ziyadeh FN[J].Semin Nephrol,2003 Nov,23(6):532
[13]Ziyadeh FN.Mediators of diabetic renal disease:the case for tgf-Beta as the major mediator[J].J Am Soc Nephrol,2004 Jan,15Suppl 1:S55
[14]Hodgkinson AD,Millward BA,Demaine AG.Polymorphism of the glucose transporter(GLUT1) gene are associated with diabetic nephropathy[J].Kiney Int,2001,59(3),985
[15]Abdel-Wahab N,Weston BS,et al.Connective tissue growth factor and regulation of the mesangial cell cycle:role in cellular hypertrophy [J].J Am Soc Nephrol,2002,13(10):2437
[16]Okada S,Shikata K,et al.Intercellular adhesion molecule-1-deficient mice are resistant against renal injury after induction of diabetes[J].Diabetes,2003 Oct,52(10):2586
[17]Forbes JM,Cooper ME,et al.Role of advanced glycation end products in diabetic nephropathy[J].J Am Soc Nephrol,2003,14(8 Supp 13):S254
[18]Omoto S,Nomura S,et al.Significance of platelet-derived microparticles and activated platelets in diabetic nephropathy[J].Nephron,1999,81(3):271
[19]郭赛珊.治疗糖尿病肾病的经验体会.中国中西医结合杂志,1996,16(1):3
[20]吕仁和,时振声.糖尿病肾病的中医诊治[J].北京中医,1989,8(2):8-10
[21]林兰.中西医结合糖尿病学.北京:中国医药科技出版社.1999:394
[22]熊曼琪,苗理平.加味桃核承气汤对糖尿病鼠肾超微结构的影响[J].中国医药学报,1990,5(5):25-27
[23]张泽生,袁遵守,杨新军,等.益肾扶脾化瘀降浊法治疗糖尿病肾病64例临床观察.新中医.2001,33(11):36
[24]林兰.糖尿病中西医结合论治[M].北京:北京科学技术出版社1992,229.
[25]高彦彬,易京红.糖肾宁治疗糖尿病肾病的临床研究.中医杂志,1991,32(7):31
[26]苏小惠.中西医结合治疗糖尿病肾病40例临床观察.辽宁中医杂志.2006,33(1):92-93
[27]王国芝,张莉,屈云.糖尿病肾病的中西医结合治疗的临床研究[J].现代中医药,2003,(4):36-38
[28]张焱.中西医结合治疗糖尿病肾病30例的临床观察.生临床和实验医学杂志.2006,5(4):402-403
[29]陈望善,杨玉霞,李华.中西医结合治疗糖尿病肾病的临床观察.湖北中医杂志.2004,26(12):9-10
[30]胡宝峰,李秋英,任小强,等.补阳还五汤加味治疗早期糖尿病肾病56例.陕西中医,2005,26(12):1281-1282
[31]石焕玉,朱晓勇.大柴胡汤加减治疗Ⅳ期糖尿病肾病32例疗效观察.中医杂志.2004,45(3):195-196
[32]吴钧俊.济生肾气丸加味治疗临床期糖尿病肾病40例疗效观察.中药新药与临床药理.2003,14(3):205-206
[33]陈辉崇,刘柏炎,加味地黄汤治疗早期糖尿病肾病32例,湖南中医杂志.2004,第20(2):36-37
[34]林楠,宋王宣,薛丽.通心络胶囊治疗糖尿病肾病疗效观察.中国误诊学杂志.2005,5(9):1663-1664
[35]宋晓燕,陈蔷,齐晓燕.六味地黄丸对早期糖尿病肾病患者红细胞醛糖还原酶活性的影响.中国中西医结合杂志.2004,24(12):1087-1090
[36]陈弼沧,吴秋英.血府逐瘀口服液治疗糖尿病肾病的临床观察.吉林中医药.2003,23(1):15-16
[37]许建秦,朱海慧,阿魏酸钠配合降糖药治疗糖尿病肾病22例,陕西中医.2005,26(8):751-753
[38]尹红梅.川芎嗪与山莨菪碱治疗糖尿病肾病40例.临床荟萃.2000,15(12):553-554
[39]黄各宁,陈积优,张镁元.灯盏花素注射液对糖尿病肾病血液流变学影响的临床研究.新.2006,38(3):34-35
[40]杨益芳.葛根素注射液治疗50例糖尿病肾病的疗效观察.泸州医学院学报.2003,26(1):44-45
[41]曹骥翔,唐新玉,丁亮,等.黄芪、生脉注射液联合苯那普利治疗糖尿病肾病32例疗效观察.湖南中医药导报.2002,8(10):596-597
[41]杨燕,邸阜生,李坤.静黄芪丹参注射液与开博通联合应用治疗糖尿病肾病. 临床观察天津医科大学学报.2000,6(1):79-81
[42]史伟,唐爱华,吴金玉,等.水蛭注射液治疗糖尿病肾病57例疗效观察.新中医.2006,38(3):38-40
[43]马为,唐桂军,郭泉滢.杏丁注射液治疗糖尿病肾病52例.中医研究.2004,17(2):31-32
[44]刘香春.中药灌肠法治疗糖尿病肾病肾功能不全30例.四川中医.2006,24(4):68-69
[45]王秀霞,李富英.中药灌肠合灸神厥穴对糖尿病晚期肾病的影响.山东医药.2006,46(28):72
[1].Yokozawa T,Nakagawa T,Wakaki K,et al.Animal model of diabetic nephropathy[J].Exp Toxicol Pathol,2001,53(5):359-363
[2]郑学民,林毅,乔文军,等.糖尿病大鼠早期肾病模型的实验研究[J].中国实验动物学杂志,2002,12(5):288-291
[3]Maeda M,Yabuki A,Suzuki S,et al.Renal lesions in spontaneous insulin-dependent diabetes mellitus in the nonobese diabetic mouse:acute phase of diabetes[J].Vet Pathol,2003,40(2):187-195
[4]Cohen MP,Sharma K,Guo J,et al.The renal TGF-beta system in the db/db mouse model of diabetic nephropathy[J].Exp Nephrol,1998,6(3):226-233
[5]吴永贵,林善锬,周江华,等.苯那普利对糖尿病大鼠肾小管间质损伤的保护作用及机制[J].中华内分泌代谢杂志,2003,19(5):406-407
[6]Sato N,Komatsu K,Kurumatani H.Late onset of diabetic nephropathy in spontaneously diabetic GK rats[J].Am J Nephrol,2003,23(5):334-342
[7]Nobrega MA,Fleming S,Roman RJ,et al.Initial characterization of a rat model of diabetic nephropathy[J].Diabetes,2004,53:735-742
[8]Schafer S,Linz W,Bube A,et al.Vasopeptidase inhibition prevents nephropathy in Zucker diabetic fatty rats[J].CardiovascRes,2003,60(2):447-454
[9]Yagi K,Kim S,Wanibuchi H.Characteristics of diabetes,blood pressure,and cardiac and renal complications in Otsuka Long-Evans Tokushima Fattyrats[J].Hypertension,1997,29(3):728-735
[10]Pavan MV,Ghin B,Castro M,et al.Prevention of hypertension atten -uates albuminuria and renal expression of fibronectin in diabetic spont -aneously hypertensive rats[J].AmJNephrol,2003,23(6):422-428
[11]Gross ML,Ritz E,Schoof A,et al.Comparison of renal morphology in the streptozotocin and the SHR/N-cp models of diabetes[J].Lab Invest, 2004,84:452-464
[12] Raz I, Wexler I, Weiss O, et al. Role of insulin and the IGF system In renal hypertrophy in diabetic Psammomys obesus (sand rat) [J].Nephrol Dial Transplant, 2003,18(7):1293-1298
[13] Cusumano AM, Bodkin NL, Hansen BC, et al. Glomerular hyper- trophy is associated with hyperinsulinemia and precedes overt diabetes in aging rhesus monkeys [J]. Am J Kidney Dis, 2002, 40 (5):1075-1085
[14] Kelly DJ, Wilkinson-Berka JL, Allen TJ, et al. A new model of diabetic nephropathy with progressive renal impairment in the transg -enic (mRen-2)27 rat (TGR)[J]. Kidney Int, 1998, 54:343-352
[15] Wogensen L, Nielsen CB, Hjorth P, et al. Under control of the renal promoter, locally produced transforming growth factor-betal induces accumulation of glomerular extracellular matrix in transgenic mice [J]. Diabetes, 1999, 48(1):182-192
[16]Yamamoto Y, Kato I, Doi T, et al. Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice [J]. J Clin Invest, 2001,108:261-268
[17] Trachtman H, Futterweit S, Pine E, et al. Chronic diabetic nephrop-athy: role of inducible nitric oxide synthase [J]. Pediatr Nephrol,2002,17(1): 20-29
[18]Ng DP, Hardy CL, Burns WC, et al. Prevention of diabetes-induced albuminuria in transgenic rats overexpressing human aldose reductase [J]. Endocrine, 2002, 18(1): 47-56
[19]Doublier S, Seurin D, Fouqueray B, et al. Glomerulosclerosis in mice transgenic for human insulin-like growth factor-binding protein-1 [J]. KidneyInt, 2000,57:2299-2307
[20] Pugliese G, Pricci F, Iacobini C, et al. Accelerated diabetic glomerulopathy in galectin-3/AGE receptor 3 knockout mice [J]. FASEB,2001, 15:2471-2479
[21]Daniel PE.Diabetes mellitus(M).5th ed.Beijing:Science Press,2000.971-1008
[22]Jean DW,Daniel WF,Henry MK,et al.Williams textbook of endocrine -fogy(M) 9th ed.Bei.jing:Science Press,2001,1014 -1022
[23]孙建红,何戎华,任传路.虫草制剂和开博通对糖尿病大鼠肾脏功能和形态影响的对比研究.徐州医学院学报,2000,20(6):450-453
[24]张振忠,豆小妮,赵宏波,等.参芪糖肾安胶囊治疗糖尿病肾病的动物实验研究.现代中医药,2007,27(3):69-71
[25]艾智华,蔡红卫,张忠辉.大黄酸治疗大鼠糖尿病肾病的实验研究.第三军医大学学报,2004,26(4):304-306
[26]柴可夫,柴瑞.糖肾汤对糖尿病大鼠肾脏保护作用的实验研究.中医药学刊,2005,23(9):1551-1552
[27]李佑生,王文健,马宇滢,等.复方丹参滴丸防治大鼠早期糖尿病肾脏损害的研究.中成药,2007,(1):40-44
[28]屈智慧,毕黎矛,邹洪斌.长春新碱治疗糖尿病肾病大鼠的实验研究中国生物制品学杂志,2004,17(3):61-65
[29]王瑞良,张洪梅,苏青.苯那普利对糖尿病大鼠肾组织RAGE表达的影响.上海交通大学学报(医学版),2007,27(2):182-184
[30]姜宝红,苏环德,徐峰,等.Doxium及Diamicron联合应用对大鼠糖尿病肾病防治的研究.黑龙江医学,2006,30(1):10-13
[31]焦秀敏,刘宽芝.缬沙坦对2型糖尿病大鼠肾脏保护作用的研究.中国糖尿病杂志,2003,11(5):337-340
[32]李晔,甘卫华,王晓颖,等.5-羟色胺2A受体拮抗剂减轻糖尿病肾病的实验研究.肾脏病与透析肾移植杂志,2002,11(5):401-406
[33]张莹雯,谢丹,杜光,等.归芪方合苯那普利对糖尿病大鼠肾组织转化生长因子β1的影响.中国中西医结合杂志,2005年6月第25卷基础理论研究特集86-90
[34]朱国茹,石岩,马丽佳.糖肾保煎剂和雷米普利对糖尿病大鼠肾脏保护作用的对比实验.中国中医药信息杂志,2005,12(1):30-32
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |